High-risk surgical stage 1 XXXX : outcomes with vault brachytherapy alone.

@entity1 @entity3490 @entity4348 @entity1204
OBJECTIVE: Prior to 1995, in our center, @entity1 with surgically staged @entity1204 with greater than 50% myoinvasion (FIGO 1C) were treated with vault brachytherapy and whole pelvis (WP) radiotherapy despite negative nodes. After October 1, 1995, these @entity1 were treated with vault brachytherapy alone. The aim of this study was to ensure that the survival and recurrence rate had not changed. METHODS: A retrospective review of Cancer Care Manitoba charts was undertaken. All @entity1 diagnosed with @entity4348 between October 1, 1995, and @entity3490 , 2001, were reviewed. Data for all FIGO surgical stage 1 @entity1 , and a subset of stage 1C @entity1 , were analyzed and compared with those of a historical control group, composed of @entity1 data previously collected in our center (1978 to 1990) [Gynecol. Oncol. 55 (1994), 51]. RESULTS: A total of 172 @entity1 had negative selective pelvic lymphadenectomy and FIGO stage 1 disease. Fifty-three stage 1C @entity1 were spared WP radiotherapy. Median follow-up was 32 months. Recurrence rate in FIGO stage 1 disease was 2.3% (4/172) and for the subset 1C was 5.7% (3/53). The recurrence rate was not statistically significantly different from that of the historical control group, 3.6% for stage 1 (P = 0.562) and 7.2% for stage 1C (P = 0.51). Two- and five-year survival rates for stage 1 @entity1 in this study were 97 and 95%, respectively. In the historical group, 2- and 5-year survival rates were 97 and 94%. CONCLUSION: Whole pelvis radiotherapy can be safely omitted in @entity1 with FIGO stage 1C @entity1204 if nodal status is known.
